HOME ·

02005.HK

SSY GROUP (02005.HK): Nimodipine oral solution wins production nod
Tags：
SSY Group02005.HKR&D Progress
2026-10-08
SSY GROUP (02005.HK): Ziprasidone Mesylate Approved for Registration as API for Use in Marketed Formulations
Tags：
SSY Group02005.HKR&D Progress
2026-09-16
SSY GROUP (02005.HK): Wins NMPA approval for Letermovir Injection, deemed to have passed consistency evaluation
Tags：
SSY Group02005.HKR&D Progress
2026-09-10
SSY GROUP (02005.HK): Trustee Purchases 1.2 Million Shares on Open Market
Tags：
SSY Group02005.HKShare Buyback
2026-09-02
SSY GROUP (02005.HK): Trustee purchases 1,000,000 shares under restricted share award scheme for approximately HKD 2.73 million
Tags：
SSY Group02005.HKShare Award Scheme
2026-09-01
SSY GROUP (02005.HK): Trustee Purchases 900,000 Shares for Approximately HKD 2,414,700 under Restricted Share Award Scheme
Tags：
SSY Group02005.HKShare Awards
2026-08-31
SSY GROUP (02005.HK): Gadobutrol injection and indocyanine green for injection approved, enhancing imaging and critical care product portfolio
Tags：
SSY Group02005.HKClinical Progress
2026-08-27
SSY GROUP(02005.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at HKD 320.32 million, YoY increase of 12.99%
Tags：
SSY Group02005.HKprofit growth
2026-08-26
SSY GROUP (02005.HK): Obtains production registration approval for sodium ozagrel injection, achieving full dosage form coverage
Tags：
SSY Group02005.HKdrug registration application
2026-08-25
SSY GROUP (02005.HK): Vitamin K1 Injection obtains NMPA drug production registration certificate, deemed to pass consistency evaluation
Tags：
SSY Group02005.HKPharmaceutical
2026-08-20
SSY Group Limited (02005.HK): Ziprasidone Hydrochloride API Approved for Marketing
Tags：
SSY Group Limited02005.HK
2026-08-07
SSY GROUP (02005.HK): Four Products Receive NMPA Drug Manufacturing Registration Approvals, Deepening Infusion Therapy and Ophthalmology Portfolio
Tags：
SSY Group02005.HKdrug registration application
2026-08-06
SSY Group (02005.HK): All 16 Specifications of 13 Pharmaceutical Varieties Proposed to Be Selected in the 12th National Centralized Drug Procurement
Tags：
SSY Group02005.HKproposed to be selected
2026-08-03
SSY Group (02005.HK): Cimetidine Injection and Acetylcysteine Solution for Inhalation Obtain Manufacturing Registration Approvals
Tags：
SSY Group02005.HKmanufacturing registration approval certificate
2026-07-30
SSY GROUP (02005.HK): Four Products Obtain NMPA Manufacturing Registration Approvals, All Deemed to Have Passed Consistency Evaluation
Tags：
SSY Group02005.HKmanufacturing registration approval certificate
2026-07-23
SSY GROUP (02005.HK): Gadobutrol API Approved for Registration by NMPA, a New-Generation Macrocyclic MRI Contrast Agent
Tags：
SSY Group02005.HKActive Pharmaceutical Ingredient
2026-07-21
SSY GROUP (02005.HK): Choline Fenofibrate Sustained-release Capsule Obtains Drug Production Registration Approval
Tags：
SSY Group02005.HKdrug production registration approval
2026-07-16
SSY GROUP (02005.HK): Baloxavir Marboxil API Approved for Registration, Becoming the Third Domestic Enterprise with Such Approval
Tags：
SSY Group02005.HKdrug registration approval
2026-07-13
SSY GROUP (02005.HK): Propylthiouracil Tablets and Calcium Gluconate and Sodium Chloride Injection Obtain Drug Registration Approvals, Deemed to Have Passed Consistency Evaluation
Tags：
SSY Group02005.HKdrug registration approval
2026-07-10
SSY GROUP (02005.HK): 95 Varieties Included in National Essential Medicines List (2026 Edition)
Tags：
SSY Group02005.HKPharmaceutical Updates
2026-07-10
12